Drugs Made In America Acquisition Corp. Rights (DMAAR)
DMAAR trades on Nasdaq in Finance, Blank Checks. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$0.1249
+11.02% on the day
Market cap
Right: not a share of the company
Revenue
Right: not a share of the company
Net income
Right: not a share of the company
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | DMAAR on Nasdaq |
| Sector | Finance |
| Industry | Blank Checks |
| Country | United States |
| IPO year | 2025 |
| SEC CIK | 0002028614 |
| SEC industry code | Blank Checks |
Financials
Right: not a share of the company.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS | 424B4 | 2025-01-29 |
| Latest annual report ANNUAL REPORT | 10-K | 2026-04-15 |
| Latest quarterly / interim QUARTERLY REPORT | 10-Q | 2026-08-14 |
| Latest current report CURRENT REPORT | 8-K | 2026-09-14 |
| Latest proxy PROXY STATEMENT | DEF 14A | 2026-04-14 |
Source: SEC EDGAR submissions feed, 78 recent filings. All filings on EDGAR.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| DMAA | Drugs Made In America Acquisition Corp. | $10.86 |
Peers in Blank Checks
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| DMII | Drugs Made In America Acquisition II Corp. | $10.19 | 0.00% | $649.1M |
| GUAC | Berto Acquisition Corp. II | $9.91 | 0.00% | $390.3M |
| TACO | Berto Acquisition Corp. | $10.47 | +0.14% | $381.7M |
| PRE | Prenetics Global Limited Class A Ordinary Share | $21.27 | +0.52% | $360.3M |
| IRHO | Iron Horse Acquisitions II Corp. | $10.07 | +0.05% | $295.3M |
| FGII | FG Imperii Acquisition Corp. | $10.03 | +0.10% | $290.3M |
| APMC | AmperCap Acquisition Company | $9.96 | 0.00% | $198.8M |
| QRED | QuasarEdge Acquisition Corporation | $10.08 | +0.10% | $161.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier